11Apr
06Apr
Astrocyte Announces Initiation of an Extended Infusion Phase 1B Study of AST-004 for Stroke and Traumatic Brain Injuries
Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, is pleased to announce the initiation of a Phase 1B study of its lead candidate, AST-004, as an extended infusion in healthy volunteers. This adaptive-design clinical study will be conducted over the next four to six months at the QPS clinical research site in Groningen, Netherlands. AST-004 is a small molecule adenosine A3/A1 receptor agonist that has consistently shown promising cerebroprotective results...
06Apr
Clinical study shows Xylyx Bio’s Matrikynes® significantly improves the structure, function, and appearance of skin
Xylyx Bio, a regenerative medicine company developing breakthrough technologies for organ and tissue repair, today announced findings from an independent clinical study that validated that their proprietary Matrikynes® ingredient is safe and highly effective for anti-aging and other topical skin applications. Results from the study are reported in the white paper "Clinical evaluation of Matrikynes®: a novel cosmetic ingredient comprised of matrikine peptides". Developed through biomedical research aimed at better understanding and promoting tissue repair and wound healing, Matrikynes® is...
05Apr
Aras Innovator Enables OnWatch Scout, an Award-winning Advanced Monitoring Solution at MacGregor
Aras, which provides the most powerful low-code platform with applications to design, build and operate complex products, today announced that MacGregor, a leader in sustainable maritime cargo and load handling, utilized Aras Innovator® to further develop its OnWatch Scout, a condition-based and predictive maintenance service. OnWatch Scout unites performance data from essential equipment aboard a ship and provides real-time condition and predictive monitoring information to the crew. OnWatch Scout was developed by MacGregor as a step in the company's digital...
05Apr
Two Babson Ventures Named Startups to Watch by BostInno
BostInno recently named two ventures founded by Babson alumni—High Time Foods and DetraPel—as startups to watch for 2023. In all, BostInno spotlighted 23 Boston companies. “All of the companies BostInno highlighted this year have different goals, products, and team cultures,” the Boston-based business publication wrote, “but the common thread is that they are on the verge of breaking out.” Co-founded by Aakash Shah MBA’22 and Damian Felchlin MBA’21, High Time Foods is a provider of shelf-stable, plant-based meat. David Zamarin...
04Apr
Elizabeth Banks shares a sunset view during tropical getaway
Following the massive success of her latest directing work, Elizabeth ensured she got a good refresh before tackling more projects, jetting off somewhere very tropical for her most recent vacation. Posing with a background of lush greenery and a stunning orange sunset on the horizon, Elizabeth looked stunning while going completely makeup-free. Although it’s evident the star knows how to kick back and have a good time and is skilled on the movie sets, Elizabeth has lent her famous name...
30Mar
IBM Cloud and Wasabi Partner to Power Data Insights Across Hybrid Cloud Environments
IBM and Wasabi Technologies, the hot cloud storage company, today announced they are collaborating to drive data innovation across hybrid cloud environments. This collaboration aims to allow enterprises to run applications across any environment - on-premises, in the cloud or at the edge - and help enable users to cost efficiently access and utilize key business data and analytics in real time. The Boston Red Sox will be the first to leverage the joint power of IBM Cloud Satellite® and...
28Mar
Neuraly Announces Topline Results from Phase 2 Trial of NLY01 in Parkinson’s Disease
Neuraly, a clinical-stage biotechnology company pioneering development of disease-modifying agents for neurodegenerative disorders, today announced topline results from the Phase 2 trial with NLY01 in patients with early, untreated Parkinson’s disease (PD). The primary endpoint, change from baseline to Week 36 in the sum of MDS-UPDRS Parts II (Motor Experiences of Daily Living) and III (Motor Examination) after 36 weeks of NLY01 treatment, compared to placebo, did not reach statistical significance. NLY01 was safe and well tolerated. The effect was...
28Mar
Immusoft Acquires Exclusive, Worldwide Rights to Intellectual Property for Genome Edited Primary B Cells from the University of Minnesot
Immusoft, a clinical-stage cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that it has successfully closed a license with the Regents of the University of Minnesota for the exclusive, worldwide rights to intellectual property (IP) for compositions of matter and methods to make and use genome edited primary B cells. The parent patent application is titled, “Genome Edited Primary B cell and Methods of Making and Using.” The IP includes proprietary methods that...
24Mar